Yuan et al. constructed a BCG-MUC1-based breast cancer vaccine (rBCG-MVNTR4-CD80), which significantly suppressed tumors, induced interferon production, and stimulated both CD4+ and CD8+ positive lymphocyte production [42]. This evidence concerns the gene CD4 and breast carcinoma.